Interpace Biosciences Q3 revenue $9.1M (+11% YoY); expects FY2023 revenue >$40M

INTERPACE BIOSCIENCES, INC.

2023-Q3 EPS reported -$0.02 revenue$29,931,000

Q3 net revenue $9.1M, up 11% from $8.2M; test volume up 11% YoY.
Loss from continuing ops $(0.5)M vs $(1.3)M; adjusted EBITDA $0.4M vs $0.1M.
Repaid $2.5M Comerica line of credit and $3M Terminal Payment to BroadOak; renegotiated long-term debt.
Cash balance $5.0M at Sept 30, 2023; cash collections $9.8M vs $7.6M.
Expects full-year 2023 revenue to exceed $40M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTERPACE BIOSCIENCES, INC. reported nine months ended September 30, 2023 results: revenue $29.9 million. Guidance reaffirmed.

Period: nine months ended September 30, 2023
Revenue: $29.9 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

For the Nine Months Ended September 30, 2023 as Compared to the Nine Months Ended September 30, 2022 ● Net Revenue was $29.9 million, an increase of 27% from $23.5 million for the prior year

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTERPACE BIOSCIENCES, INC. reported third quarter ended September 30, 2023 results: revenue $9.1 million. Guidance reaffirmed.

Period: third quarter ended September 30, 2023
Revenue: $9.1 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

in such filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results ● Q3 Revenue of $9.1 million; an 11% increase year-over-year ● Q3 Test volume up 11% year-over-year ● Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and

View on SEC.gov

Browse all earnings releases →

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-039945

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.